Liver and spleen stiffness measurements in patients with BCR-ABL-negative myeloproliferative neoplasms and their clinical significance / 中国基层医药

ABSTRACT

Objective:To measure liver and spleen stiffness in patients with BCR-ABL-negative myeloproliferative neoplasms and analyze their clinical significance.Methods:Fifteen healthy volunteers and 27 patients with BCR-ABL-negative myeloproliferative neoplasms underwent liver and spleen thickness measurements using FibroScan 502 Touch medical device between June 2018 and June 2020 in Hebei Petro China Central Hospital and they were included in this study. Liver and spleen stiffness was correlated with clinical laboraty indicators.Results:Liver stiffness, spleen stiffness, and the difference between spleen stiffness and liver stiffness in patients with BCR-ABL-negative myeloproliferative neoplasms were significantly greater than those in healthy controls [(6.34 ± 2.22) kPa vs. (5.07 ± 1.27) kPa; (26.00 ± 10.66) kPa vs. (13.61 ± 5.64) kPa; (19.65 ± 10.37) kPa vs. (8.54 ± 5.33) kPa, t = -2.01, -4.30, -4.06, all P < 0.05]. Platelet count was negatively correlated with liver and spleen stiffness ( r = -0.39, -0.42). White blood cell count was negatively correlated with the difference between spleen stiffness and liver stiffness ( r = -0.40, P < 0.05). The uric acid level was negatively correlated with liver stiffness ( r = -0.54, P < 0.05), but it was positively correlated with spleen thickness ( r = 0.41, P < 0.05). The percentage of B lymphocytes among lymphocytes was negatively correlated with spleen stiffness and the difference between spleen stiffness and liver stiffness ( r= -0.56, -0.56, both P < 0.05). The percentage of diseased megakaryocytes was positively correlated with spleen stiffness ( r = 0.40, P < 0.05). The percentage of sideroblasts was negatively correlated with liver stiffness ( r = -0.44, P < 0.05). Conclusion:Spleen stiffness and liver stiffness are closely related to clinical indicators in patients with BCR-ABL-negative myeloproliferative neoplasms, including white blood cell count, platelet count, uric acid level, percentage of B lymphocytes, diseased megakaryocytes and sideroblasts. Dynamic monitoring of liver and spleen stiffnesses or in combination with bone marrow examination in future can help evaluate the condition of patients with BCR-ABL-negative myeloproliferative neoplasms.